IBANDRONATE SODIUM (ibandronate sodium)

There are 0 contraindications.

Drug contraindication overview.

Hypocalcemia or known hypersensitivity to ibandronate or any ingredient in the formulation. With oral ibandronate, abnormalities of the esophagus that delay esophageal emptying, such as stricture or achalasia. With oral ibandronate, inability to stand or sit upright for at least 60 minutes.

Adverse reaction overview.

Adverse effects occurring in at least 2% of patients receiving daily oral ibandronate therapy in osteoporosis treatment or prevention studies and in more patients than with placebo include upper respiratory tract infection, back pain, dyspepsia, bronchitis, pain in the extremities, diarrhea, headache, pneumonia, myalgia, urinary tract infection, hypercholesterolemia, infection (unspecified), dizziness, joint disorder, asthenia, tooth disorder, arthritis, vertigo, vomiting, allergic reaction, pharyngitis, gastritis, and nerve root lesion. Adverse effects occurring in at least 2% of patients receiving once-monthly oral ibandronate include upper abdominal or abdominal pain, hypertension, dyspepsia, arthralgia, nausea, diarrhea, back pain, constipation, influenza, pain in the extremities, nasopharyngitis, headache, influenza-like illness and acute phase inflammatory reaction, localized osteoarthritis, bronchitis, urinary tract infection, dizziness, rash (including pruritic, macular, papular, erythematous, or generalized rash; dermatitis or allergic dermatitis; exanthem; erythema; and dermatitis medicamentosa), myalgia, upper respiratory tract infection, and insomnia. Adverse effects occurring in at least 2% of patients receiving quarterly IV ibandronate therapy for the treatment of osteoporosis include arthralgia, back pain, cystitis, gastroenteritis, upper abdominal or abdominal pain, influenza-like illness and acute phase inflammatory reaction, headache, dyspepsia, nasopharyngitis, constipation, fatigue, diarrhea, pain in the extremities, myalgia, urinary tract infection, osteoarthritis, rash (including pruritic, macular, papular, erythematous, or generalized rash, dermatitis or allergic dermatitis, exanthem, erythema, and dermatitis medicamentosa), bronchitis, and nausea.

Safety and efficacy have not been established in children. Ibandronate is not indicated for use in children.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None